Related Experiment Video
Updated: May 13, 2026
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
[Progress of anti-tumor study based on BRAF]
Gui-Rui Yan1, Zhi-Jian Xu, He-Yao Wang
1Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Abstract:
BRAF is one of the most important pro-oncogenes, which is mutated in approximately 8% of human tumors. The most common BRAF mutation is a valine-to-glutamate transition (V600E) that is expressed primarily in melanoma, colorectal cancer and thyroid carcinoma. MEK/ERK is constitutively activated in the cells expressing BRAFV600E, leading to tumor development, invasion, and metastasis. Therefore, BRAFV600E is a therapeutic target for melanoma and some other BRAFV600E tumors. Vemurafenib, a BRAFV600E inhibitor, which was approved by FDA for the treatment of late-stage melanoma in 2011, produces improved rates of overall and progression-free survival in patients with the BRAFV600E mutation, making a dramatic breakthrough in melanoma treatment. Vemurafenib is also an individual target drug based on genetic diagnosis. However, its therapeutic success is limited by the emergence of drug resistance. Therefore, it is important to explore the mechanisms underlying the resistance for developing new inhibitor drugs and for preventing or delaying the resistance evolution to BRAF inhibitor drugs. In this review, we described the role of BRAFV600E as an anti-tumor drug target and the development of BRAF inhibitors. We also discussed the mechanisms leading to resistance of BRAFV600E inhibitors. Furthermore, therapeutic strategies that might be employed to overcome acquired resistance were proposed.
Insights
BRAF V600E mutations drive tumor growth and are targeted by drugs like Vemurafenib. Understanding resistance mechanisms is key to developing new therapies for BRAF-mutated cancers.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- BRAF is a key oncogene, with the V600E mutation found in ~8% of human tumors, notably melanoma, colorectal, and thyroid cancers.
- BRAFV600E activates the MEK/ERK pathway, promoting tumor development, invasion, and metastasis, making it a critical therapeutic target.
Purpose of the Study:
- To review the role of BRAFV600E as an anti-tumor target and the evolution of BRAF inhibitors.
- To discuss mechanisms of acquired resistance to BRAF inhibitors.
- To propose strategies for overcoming resistance to BRAF-targeted therapies.
Main Methods:
- Literature review of BRAF oncogene, BRAF inhibitors, and resistance mechanisms.
- Analysis of therapeutic strategies for BRAF-mutated cancers.
- Synthesis of current knowledge on BRAF inhibitor resistance.
Main Results:
- BRAFV600E is a validated therapeutic target, with inhibitors like Vemurafenib showing clinical benefit in melanoma.
- Drug resistance remains a significant limitation to the long-term efficacy of BRAF inhibitors.
- Multiple mechanisms contribute to acquired resistance, necessitating further research.
Conclusions:
- BRAF inhibitors represent a breakthrough in treating BRAFV600E-mutated cancers, but resistance limits their success.
- Understanding resistance pathways is crucial for developing next-generation inhibitors and combination therapies.
- Future strategies should focus on overcoming acquired resistance to improve patient outcomes.
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...